Evaluation of Fluorotype MTB for detection of Mycobacterium tuberculosis complex DNA in clinical specimens from a low-incidence country

BMC Infectious Diseases

Harald Hoffmann¹  Sabine Hofmann-Thiel¹ 

[1] synlab MVZ Gauting, IML red, WHO Supranational Reference Laboratory of Tuberculosis, Robert-Koch-Allee 2, 82131 Gauting, Germany

关键词: Respiratory;    Fluorotype MTB;    Nucleic acid amplification;    PCR;    NAAT;    MTBC;    TB diagnostics;    Mycobacterium tuberculosis complex;   

Others  :  1134760
DOI  :  10.1186/1471-2334-14-59

 received in 2013-10-05, accepted in 2014-01-30,  发布年份 2014

【 摘 要 】

Background

With Fluorotype MTB (FT MTB, HAIN Lifesciences, Germany) a new semi-automated assay for detection of M. tuberculosis complex (MTBC) in clinical specimens has been introduced. In a prospective study, we evaluated the diagnostic performance of FT MTB in a routine diagnostic setting in a low-incidence country.

Methods

A total of 1039 respiratory specimens received for routine mycobacteriology diagnostics were analysed by FT MTB. Results were compared to those of culture, microscopy and clinical diagnosis. 61 specimens were excluded from further analysis due to bacterial contamination of cultures.

Results

FT MTB detected 52 of 59 TB specimens (45 culture-positive with MTBC, 7 with clinical diagnosis of TB). With 902 of 912 non-TB specimens (884 culture-negative, 18 with growth of non-tuberculous mycobacteria) FT MTB was negative; discrepant positive FT MTB results were found with 10 specimens. Overall sensitivity, specificity, positive and negative predictive values were 88.1%, 98.9%, 83.8% and 99.2%. Sensitivity rates for smear-positive and smear-negative TB specimens were 100% and 56.3%, respectively. Seven of 978 samples (0.7%) yielded invalid FT MTB results.

Conclusions

FT MTB is a new accurate, half automated assay for rapidly diagnosing TB and suitable for larger series of samples. Performance characteristics were found to be similar to those of other commercial NAATs. Its sensitivity in paucibacillary, smear-negative specimens and its utility for TB diagnostics in high-incidence settings needs to be addressed in further studies.

【 授权许可】

   
2014 Hofmann-Thiel and Hoffmann; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NT, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D: Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010, 48:229-237.
• [2]Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodriques C, Alland D, Perkins MD: Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
• [3]Robert Koch Institut: Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2011. Berlin: Robert Koch Institut; 2013.
• [4]Tortoli E, Urbano P, Marcelli F, Simonetti TM, Cirillo DM: Is real-time PCR better than conventional PCR for Mycobacterium tuberculosis complex detection in clinical samples? J Clin Microbiol 2012, 50:2810-2813.
• [5]Yang YC, Lu PL, Huang SC, Jenh YS, Jou R, Chang TC: Evaluation of the Cobas TaqMan MTB test for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011, 49:797-801.
• [6]Goessens WHF, de Man P, Koeleman GM, Luijendijk A, te Witt R, Endtz HP, van Belkum A: Comparison of the COBAS AMOLICOR MTB and BDProbeTec ET assays for detection of mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol 2005, 43:2563-2566.
• [7]Piersimoni C, Callegaro A, Scarparo C, Penati V, Nista D, Bornigia S, Lacchini C, Scagnelli M, Santini G, De Sio G: Comparative evaluation of the new gen-probe Mycobacterium tuberculosis amplified direct test and the semiautomated abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in respiratory and extrapulmonary specimens. J Clin Microbiol 1998, 6:3601-3604.
• [8]Causse M, Ruiz P, Gutierrez-Aroca JB, Casal M: Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. J Clin Microbiol 2011, 49:3065-3067.
• [9]Park KS, Kim JY, Lee JW, Hwang YY, Jeon K, Koh WJ, Lo CS, Lee NY: Comparison of the Xpert MTB/RIF and Cobas TaqMan MTB Assays for Detection of Mycobacterium tuberculosis in Respiratory Specimens. J Clin Microbiol 2013, 51:3225-3227.
• [10]Antonenka U, Hofmann-Thiel S, Turaev L, Esenalieva A, Abdulloeva M, Sahalchyk E, Alnour T, Hoffmann H: Comparison of Xpert MTB/RIF with ProbeTec ET DTB and COBAS TaqMan MTB for direct detection of M. tuberculosis complex in respiratory specimens. BMC Infect Dis 2013, 13:280. BioMed Central Full Text
• [11]Luh KT, Hsueh PR, Hsu HL, Lee LN, Wang JY: Performance assessment of the DR.MTBC Screen assay and the BD ProbeTec ET system for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol 2006, 44:716-719.
• [12]Piersimoni C, Callegaro A, Nista D, Bornigia S, De Conti F, Santini G, De Sio G: Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 1997, 35:193-196.
• [13]Reischl U, Lehn N, Wolf H, Naumann L: Clinical evalution of automated COBAS AMPLICOR MTB assay for testing respiratory and nonrespiratory specimens. J Clin Microbiol 1998, 36:2853-2860.
• [14]Rüsch-Gerdes S, Richter E: Clinical evaluation of the semiautomated BDProbeTec ET System for the detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. Diagn Microbiol Infect Dis 2004, 48:265-270.
• [15]Kim JH, Kim YJ, Ki CS, Kim JY, Lee NY: Evaluation of Cobas TaqMan MTB PCR for detection of Mycobacterium tuberculosis. J Clin Microbiol 2011, 49:173-176.
• [16]Kerleguer A, Koeck JL, Fabre M, Gerome P, Teyssou R, Herve V: Use of equivocal zone in interpretation of results of the amplified mycobacterium tuberculosis direct test for diagnosis of tuberculosis. J Clin Microbiol 2003, 41:1783-1784.
• [17]Lara-Oya A, Mendoza-Lopez P, Rodriguez-Granger J, Fernandez-Sanchez AM, Bermudez-Ruiz MP, Toro-Peinado I, Palop-Borrás B, Navarro-Marí JM, Martínez-Lirola MJ: Evaluation of the speed-oligo direct Mycobacterium tuberculosis assay for molecular detection of mycobacteria in clinical respiratory specimens. J Clin Microbiol 2013, 51:77-82.
• [18]Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, Ntinginya EN, O'Grady J, Huggett J, Dheda K, Boehme C, Perkins M, Saathoff E, Hoelscher M: Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay–a clinical validation study. PLOS ONE 2011, 6:e20458.
• [19]Lebrun L, Mathieu D, Saulnier C, Nordmann P: Limits of commercial molecular tests for diagnosis of pulmonary tuberculosis. Eur Respir J 1997, 10:1874-1876.
• [20]Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I: Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 2010, 10:612. BioMed Central Full Text
• [21]Thomson RM: Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010, 16:1576-1583.
• [22]Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL: Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009, 49:124-129.